Subsets of AD patients were evaluated with multimodal imaging combining MEG and positron emission tomography (PET) with tracers to quantify Aβ (11C-PIB), tau (flortaucipir), and hypometabolism (18F-FDG), and with long-term electroencephalography (LTM-EEG) with video monitoring combined with 1-hour simultaneous MEG and EEG (M/EEG) to identify epileptic activity (AD-EPI+ vs AD-EPI −). The gene discussed is MAPT; the disease is Alzheimer disease.